Dorian A. Rosen

Dorian A. Rosen

Auto-generated profile, based on publicly available information

Dorian A. Rosen

Center for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DRDorian A. Rosen
Dorian A. Rosen
SSScott M. Seki
Scott M. Seki
AFAnthony Fernández-Castañeda
Anthony Fernández-Castañeda
RBRebecca M. Beiter
Rebecca M. Beiter
JEJacob ECCLES
Jacob ECCLES
AGAlban Gaultier
Alban Gaultier
Sigma-1 receptor is a critical inhibitor of endoplasmic reticulum–driven inflammation and a potential therapeutic target in septic shock.

27 October 2020 in Science Signaling
Verified
Journal Article
Closed access
PDF file
SSScott M. Seki
Scott M. Seki
KPKacper Posyniak
Kacper Posyniak
RMRebecca McCloud
Rebecca McCloud
DRDorian A. Rosen
Dorian A. Rosen
AFAnthony Fernández-Castañeda
Anthony Fernández-Castañeda
AGAlban Gaultier
Alban Gaultier
Small molecules that promote the metabolic activity of the pyruvate kinase isoform PKM2, such as TEPP-46 and DASA-58, limit tumorigenesis and inflammation. To understand how these compounds alter T cell function, we assessed their therapeutic activity in a mouse model of T cell–mediated autoimmunity that mimics multiple sclerosis (MS). TH17 cells are believed to orchestrate MS pathology, in part, through the production of two proinflammatory cytokines: interleukin-17 (IL-17) and GM-CSF. We found that both TEPP-46 and DASA-58 suppressed the development of IL-17–producing TH17 cells but increased the generation of those producing GM-CSF. This switch redirected disease pathology from the spinal cord to the brain. In addition, we found that activation of PKM2 interfered with TGF-β1 signaling, which is necessary for the development of TH17 and regulatory T cells. Collectively, our data clarify the therapeutic potential of PKM2 activators in MS-like disease and how these agents alter T cell function.

15 June 2017 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
SSScott M. Seki
Scott M. Seki
MSMax Stevenson
Max Stevenson
ARAbagail M. Rosen
Abagail M. Rosen
SASanja Arandjelovic
Sanja Arandjelovic
LGLelisa Gemta
Lelisa Gemta
AGAlban Gaultier
Alban Gaultier
Multiple sclerosis (MS) is a disease that is characterized by immune-mediated destruction of CNS myelin. Current MS therapies aim to block peripheral immune cells from entering the CNS. Although these treatments limit new inflammatory activity in the CNS, no treatment effectively prevents long-term disease progression and disability accumulation in MS patients. One explanation for this paradox is that current therapies are ineffective at targeting immune responses already present in the CNS. To this end, we sought to understand the metabolic properties of T cells that mediate ongoing inflammation in the demyelinating CNS. Using experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice, a well-studied model of MS, we showed that the CD4+ and CD8+ T cells that invade the EAE CNS are highly glycolytic. Elevated glycolytic rates in T cells isolated from the EAE CNS correlate with upregulated expression of glycolytic machinery and is essential for inflammatory responses to myelin. Surprisingly, we found that an inhibitor of GAPDH, 3-bromopyruvic acid (3-BrPa), blocks IFN-γ, but not IL-17A, production in immune cells isolated from the EAE CNS. Indeed, in vitro studies confirmed that the production of IFN-γ by differentiated Th1 cells is more sensitive to 3-BrPa than is the production of IL-17A by Th17 cells. Finally, in transfer models of EAE, 3-BrPa robustly attenuates the encephalitogenic potential of EAE-driving immune cells. To our knowledge, these data are among the first to demonstrate the metabolic properties of T cells in the demyelinating CNS in vivo.